Adaptyv Bio offers an automated cloud lab platform that conducts protein assays and delivers clean, labeled data for AI-driven protein design within three weeks. The service integrates ordering, experiment management, and data analysis through a comprehensive API, enabling seamless incorporation into existing workflows. Transparent per‑protein pricing and real‑time progress updates help teams accelerate lab‑in‑the‑loop protein engineering cycles.

Aperiam Bio develops hyperfolding variants of proteins that significantly enhance expression, solubility, and specific activity, enabling the production of stable enzymes for various applications. Their technology addresses the instability of natural proteins in harsh conditions, ensuring over 68% activity retention in therapeutics and extending the shelf life of cosmetic ingredients.

Appiabio provides a platform that monitors deployment pipelines in real time, showing status flags such as paused, active, or failed. It integrates with existing CI/CD tools to automatically capture deployment events and delivers a centralized dashboard with configurable alerts for rapid issue response, helping development and DevOps teams streamline release coordination.

Attivare Therapeutics develops the ATTImmune platform, a biomaterial scaffold that creates a localized microenvironment to recruit, activate, and reprogram immune cells at tumor sites. By loading the scaffold with customizable immunomodulators such as cytokines, CpG or mRNA, the platform delivers 3D spatiotemporal control of immune activation, enhancing the magnitude and durability of anti‑tumor responses for low‑immunogenic cancers and potentially infectious diseases.

BigHat Biosciences utilizes a machine learning-guided antibody design platform, Milliner, which integrates synthetic biology and high-speed wet lab processes to rapidly synthesize and characterize recombinant antibodies. The company focuses on developing safer and more effective antibody therapies for patients with challenging diseases, enhancing treatment options in the biopharmaceutical landscape.

BluumBio utilizes enzyme-based bioremediation technologies to remove industrial pollutants such as petroleum, pesticides, and plastics from soil, air, and water. By harnessing naturally occurring enzymes from fungi, bacteria, and tropical trees, the company restores ecosystems and promotes biodiversity within 6-12 months of project initiation.

Bristle Health provides a comprehensive saliva test to analyze the user's oral microbiome, identifying the specific bacteria driving oral health issues. This analysis delivers root cause insights for problems like bad breath, gum disease, and cavities. Based on these results, the company furnishes a personalized action plan, including product and diet recommendations, to optimize oral wellness.

CatenaBio’s CysTyr platform enables site‑specific conjugation of two or more drug payloads to a single antibody using a stable cystine‑tyrosine (C‑Y) bond. The resulting multi‑payload ADCs support flexible drug‑to‑antibody ratios and accommodate large or complex molecules, aiming to overcome resistance and improve therapeutic index in solid‑tumor indications. The technology integrates with existing antibody manufacturing processes for pharmaceutical and biotech developers.

CHARM Therapeutics utilizes its proprietary DragonFold technology, which employs 3D deep learning for protein-ligand co-folding, to develop small molecule inhibitors targeting previously undruggable proteins associated with cancer and other diseases. By addressing the challenge of the vast majority of the human proteome remaining undruggable, the company aims to create transformative therapies for patients with high unmet medical needs.

This startup utilizes mycelium technology to convert agricultural waste into high-performance biological products, enhancing soil health and crop yields. By establishing a mushroom biorefinery in Colorado, they provide sustainable solutions that reduce waste and improve agricultural productivity.

Concerto Biosciences converts complex microbial ecology data into effective, microbe-based consumer health products. The company utilizes proprietary kChip experimental platforms and kAI modeling to generate and analyze vast ecological datasets for predictable microbial engineering. This intelligence enables the development of high-performance ingredients for applications in skin health and other chronic conditions.

Deciduous Therapeutics develops immune modulatory therapies that activate the body's natural immune mechanisms to eliminate senescent cells, which contribute to age-related diseases. By targeting these dysfunctional cells, the company aims to improve health span and mitigate the effects of inflammation and tissue remodeling associated with aging.

Delix Therapeutics develops neuroplastogens, a novel class of compounds that promote neuroplasticity to enhance brain health. Their approach targets neuropsychiatric conditions by repairing neural circuits and improving mental function through safe and fast-acting treatments.

Enable Medicine provides a cloud‑based platform that consolidates multimodal biological data—such as single‑cell, spatial, omics, imaging, and clinical metadata—into a unified atlas. Using proprietary AI/ML methods, including graph neural networks and spatial deep learning, the platform generates interpretable insights for target identification, biomarker discovery, patient stratification, and trial design, helping biopharma and academic researchers accelerate therapeutic development.

This company produces a tasteless enzyme powder designed to break down FODMAPs, which are common triggers for digestive discomfort. By degrading these carbohydrates in food, the product allows individuals to consume previously restricted items like wheat, garlic, and beans without experiencing symptoms such as bloating or gas. The solution offers an alternative to restrictive elimination diets, enabling consumers to enjoy a wider variety of meals confidently.

This company applies advanced AI and bioengineering techniques, similar to those used in pharmaceutical development, to discover novel molecules for beauty and wellness applications. Their scalable platform screens vast molecular libraries to identify new ingredients that target specific skin, hair, and wellness challenges. The resulting proprietary molecules offer superior clinical efficacy compared to existing market formulations.

Glyphic Biotechnologies develops Protein Sequencing by Expansion (ProSE™), a novel technology for high-throughput proteome sequencing. This method achieves single-molecule sensitivity for accurate discrimination of all 20 amino acids and post-translational modifications (PTMs). The platform aims to provide unprecedented precision and scalability for advancing proteomics research and therapeutic development.

HTuO Biosciences develops novel small molecule therapeutics targeting challenging protein-protein interactions in oncology and immunology. The company utilizes proprietary structure-based drug design platforms to create highly selective and potent drug candidates. This approach aims to deliver first-in-class treatments for diseases with high unmet medical need.

Inductive Bio provides a virtual laboratory platform that uses AI chemistry assistants and ADMET models to predict molecular behavior in the body. This capability allows drug discovery teams to run millions of _in silico_ experiments to surface the strongest hypotheses for wet lab testing. The platform accelerates development candidate selection by front-loading critical safety and efficacy insights before synthesis.

Infinimmune uses its Complete Human sequencing technology® to capture fully paired heavy‑light antibody sequences from up to 300 million B cells, building the world’s largest database of natural human antibodies. Its Anthrobody® library‑on‑B‑cell platform and GLIMPSE™ AI‑driven language model enable rapid selection, affinity maturation, and developability optimization, delivering fully human therapeutic candidates in as little as eight weeks for biopharma and research partners.

Insamo transforms drug discovery for challenging diseases using an automated platform for designing, synthesizing, and testing compounds. This process leverages trillions of proprietary experimental data points across vast chemical space. The company applies scalable machine learning to accelerate and set a new standard for drug design iteration cycles.

Lyell Immunopharma develops CAR T-cell therapies specifically targeting solid tumors and hematologic malignancies, addressing the significant unmet medical need for more durable cancer treatments. Their technology focuses on generating enhanced CAR T cells that aim to improve patient outcomes in oncology.

Meliora Therapeutics focuses on advancing oncology drug development for the 21st century. The company is dedicated to creating novel therapeutic solutions to address unmet needs in cancer treatment. Their work centers on bringing forward new pharmaceutical agents through rigorous development pipelines.

Provides virtual psychiatry and therapy services tailored for women, offering personalized provider matching based on individual mental health needs and goals. Accepts various insurance plans and offers affordable self-pay rates, ensuring accessible and flexible mental health care, including medication management and talk therapy.